1. Home
  2. RLAY vs DLX Comparison

RLAY vs DLX Comparison

Compare RLAY & DLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLAY
  • DLX
  • Stock Information
  • Founded
  • RLAY 2015
  • DLX 1915
  • Country
  • RLAY United States
  • DLX United States
  • Employees
  • RLAY N/A
  • DLX N/A
  • Industry
  • RLAY Biotechnology: Biological Products (No Diagnostic Substances)
  • DLX Advertising
  • Sector
  • RLAY Health Care
  • DLX Consumer Discretionary
  • Exchange
  • RLAY Nasdaq
  • DLX Nasdaq
  • Market Cap
  • RLAY 619.0M
  • DLX 719.5M
  • IPO Year
  • RLAY 2020
  • DLX N/A
  • Fundamental
  • Price
  • RLAY $3.99
  • DLX $19.60
  • Analyst Decision
  • RLAY Strong Buy
  • DLX Strong Buy
  • Analyst Count
  • RLAY 13
  • DLX 1
  • Target Price
  • RLAY $18.00
  • DLX $23.00
  • AVG Volume (30 Days)
  • RLAY 1.2M
  • DLX 274.1K
  • Earning Date
  • RLAY 11-05-2025
  • DLX 11-05-2025
  • Dividend Yield
  • RLAY N/A
  • DLX 6.12%
  • EPS Growth
  • RLAY N/A
  • DLX 49.73
  • EPS
  • RLAY N/A
  • DLX 1.28
  • Revenue
  • RLAY $8,355,000.00
  • DLX $2,106,724,000.00
  • Revenue This Year
  • RLAY $31.55
  • DLX $0.34
  • Revenue Next Year
  • RLAY N/A
  • DLX $1.60
  • P/E Ratio
  • RLAY N/A
  • DLX $15.28
  • Revenue Growth
  • RLAY N/A
  • DLX N/A
  • 52 Week Low
  • RLAY $1.78
  • DLX $13.61
  • 52 Week High
  • RLAY $8.32
  • DLX $24.45
  • Technical
  • Relative Strength Index (RSI)
  • RLAY 58.70
  • DLX 57.79
  • Support Level
  • RLAY $3.87
  • DLX $18.98
  • Resistance Level
  • RLAY $4.20
  • DLX $19.82
  • Average True Range (ATR)
  • RLAY 0.21
  • DLX 0.44
  • MACD
  • RLAY 0.03
  • DLX -0.11
  • Stochastic Oscillator
  • RLAY 66.87
  • DLX 54.96

About RLAY Relay Therapeutics Inc.

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

About DLX Deluxe Corporation

Deluxe Corporation is principally a payments and data company. Its reportable segments are; Merchant Services, B2B Payments, Data Solutions, and Print. Maximum revenue is derived from its Print segment which provides printed personal and business checks, business essentials, as well as branded promotional, print, apparel, and digital storefront solutions. The Merchant Services segment provides electronic credit and debit card authorization, payment systems, and processing services. The B2B segment offers treasury management solutions, integrated accounts payable disbursements, and fraud and security services, and the Data Solutions segment offers data, analytics, and marketing services as well as financial institution profitability reporting and business incorporation services.

Share on Social Networks: